Real-world study of Tislelizumab for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of lung cancer that can be removed with surgery (stage II-IIIA) and is at high risk of coming back, OR you have advanced or metastatic lung cancer that fits certain subtypes (like squamous NSCLC, non-squamous with high PD-L1, or extensive-stage small cell lung cancer).
- Your doctor must have already decided to treat you with Tislelizumab before you join this study.
- You cannot be in this study if you have not signed a consent form or if you don't understand what the study involves.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.
This study watches how well Tislelizumab works for people with lung cancer when it is used as part of their normal treatment. It does not give you any new medicine or change your care plan.
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new Lung Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.